NCT05104372

Brief Summary

Nasal washing (washout) followed by gargles with hypertonic saline (HSNIG) is believed to be effective in reducing the duration of illness in those with clinically suspected or confirmed COVID-19 being managed at home, and also is effective in reducing complications of COVID-19 and onward household transmission. This study plans to investigate whether the use of HSNIG performed by adults with symptoms consistent with COVID-19 reduces the duration of symptoms when compared to participants managed using standard care.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
405

participants targeted

Target at P75+ for not_applicable covid19

Timeline
Completed

Started May 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2021

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

October 25, 2021

Completed
9 days until next milestone

First Posted

Study publicly available on registry

November 3, 2021

Completed
12 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 15, 2021

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2021

Completed
Last Updated

November 3, 2021

Status Verified

November 1, 2021

Enrollment Period

7 months

First QC Date

October 25, 2021

Last Update Submit

November 1, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time to resolution of symptoms

    Self-reported time to resolution as assessed by completion of the validated self-reported UK-adapted short form of the Wisconsin Upper Respiratory Symptom Survey (WURSS-24) which will be used to collect daily symptom data

    2 weeks

Study Arms (2)

Intervention

EXPERIMENTAL

Intervention Group HSNIG started within 5 days of symptom onset Number of times HSNIG should be done: As many times as needed (but not more than 12 times/day) PLUS Standard personal, household hygiene and social distancing advice: http://www.covid.gov.pk/prevention

Other: Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)

Control

PLACEBO COMPARATOR

Control Group Standard personal, household hygiene and social distancing advice: http://www.covid.gov.pk/prevention

Other: Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)

Interventions

Nasal washout and gargles

ControlIntervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults (≥18 years)
  • Those living within larger cities of Pakistan (for laboratory access)
  • Those self-isolating at home within 5 days of the start of the illness with:
  • Clinical symptoms suggestive of COVID-19 (i.e. those who have at least one of the following symptoms: Respiratory symptoms, such as cough and shortness of breath; Fever; Muscle pain; Headache; Sore throat; New loss of taste or smell; Severe fatigue; Nausea or vomiting; Diarrhoea and Congestion or runny nose OR
  • Those with virologically confirmed SARS-CoV-2 infection and clinical symptoms indicative of COVID-19 (as detailed in (a) above).
  • Provision of informed consent

You may not qualify if:

  • Onset of illness (symptoms) more than 5 days
  • Inability to consent
  • Age less than 18 years.
  • Pregnancy
  • Immunosuppressed patients Inability to perform HSNIG
  • Those taking part in another interventional medical trial
  • Those with suspected/confirmed COVID-19 in whom hospital admission is recommended
  • Those who do not have access to email / internet
  • Those living in a household with another person currently participating in this study
  • Those who have not provided consent to take part

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Allergy and Asthma Institute, Pakistan

Islamabad, 44000, Pakistan

RECRUITING

Related Publications (1)

  • Yusuf OM, Ramalingam S, Norrie J, Graham C, Kakakhail A, Rextin AT, Baig RT, Yusuf SO, Ahmad B, Zahra S, Sheikh A. Hypertonic saline nasal irrigation and gargling for suspected or confirmed COVID-19: Pragmatic randomised controlled trial (ELVIS COVID-19). J Glob Health. 2024 Dec 13;14:05027. doi: 10.7189/jogh.14.05027.

MeSH Terms

Conditions

COVID-19

Interventions

Mouthwashes

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Biomedical and Dental MaterialsSpecialty Uses of ChemicalsChemical Actions and UsesCosmeticsManufactured MaterialsTechnology, Industry, and Agriculture

Study Officials

  • Aziz Sheikh, MD, PhD

    University of Edinburgh

    STUDY CHAIR

Central Study Contacts

OSMAN M YUSUF, MBBS, PhD

CONTACT

Aimal T Rextin, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: A randomised intervention and a control arm, running in parallel
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief Consultant

Study Record Dates

First Submitted

October 25, 2021

First Posted

November 3, 2021

Study Start

May 1, 2021

Primary Completion

November 15, 2021

Study Completion

November 30, 2021

Last Updated

November 3, 2021

Record last verified: 2021-11

Data Sharing

IPD Sharing
Will not share

The study is anonymized, and individual participant data (IPD) will not be available to other researchers.

Locations